Lawsuit says Novo, OptumRx ‘mutually benefited’ from rebate scheme, while consumers paid the price Novo Nordisk is the target, along with pharmacy benefit manager OptumRX, of a new proposed class […]
Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since […]
Safety profile will help bring ozanimod to multiple sclerosis market, says Celgene Missing a secondary endpoint in the RADIANCE trial won’t hinder the launch or commercial success of ozanimod, CFO […]
Gottlieb ends FDA hiring freeze, lays out R&D priorities Scott Gottlieb, M.D., has ended the hiring freeze President Donald Trump imposed on the FDA. The action means Gottlieb can fill […]
Chutes & Ladders—Alexion’s C-suite overhaul involves CFO, R&D head Alexion experienced a major C-suite overhaul that included its CFO, CCO, R&D head and HR chief; Van Oene’s title as Illumina’s […]